Brief: Resverlogix Exceeds Full Enrollment For The Pivotal Phase 3 Betonmace Clinical Trial
19/03/2018 11:14
March 19 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE
3
BETONMACE CLINICAL TRIAL
* RESVERLOGIX CORP - EXPLORING OPTION OF US ENROLLMENT IN
BETONMACE TRIAL AS WELL AS OPTION OF RELYING ON EXISTING
BETONMACE DATA TO FILE A US NDA
* RESVERLOGIX CORP - PRIMARY ENDPOINT READ-OUT OF ONGOING
PHASE
3 BETONMACE TRIAL AROUND END OF 2018
Source text for Eikon: ID:nGNXbqjDLY
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment